Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937
about
The plasminogen activator inhibitor-2 gene is not required for normal murine development or survivalPlasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cellsCloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitorThe receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexesHuman monocyte Arg-Serpin cDNA. Sequence, chromosomal assignment, and homology to plasminogen activator-inhibitorFacultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditionsPlasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.Urokinase-dependent adhesion loss and shape change after cyclic adenosine monophosphate elevation in cultured rat mesangial cells.Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin.Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoterPhorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor.Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells.The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity.Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulence.Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors.The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene.Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts.Inactivation of human tumor cell pro-urokinase by granulocyte elastase.urokinase plasminogen activator (two-chain):uPAR + plasminogen activator inhibitor 2 (PAI-2) -> PAI-2:urokinase plasminogen activator (two-chain):uPAR
P2860
Q24554422-8DA322FD-B57F-438E-A08C-40BA32D3FB6FQ24612910-D87C3A04-FB07-4910-B0BA-FDD4B311DB46Q24655336-05E4DB8C-2866-41A6-A495-C36789614282Q24678932-A2FBA42B-65C2-4A08-8DCB-CB06C82C5C78Q24682654-7B878C9E-0217-446C-B81F-7DB556843277Q33584270-BA4435DC-79F1-4F5C-86C5-A39477E279F2Q33848822-F52482CA-5FE4-4714-A183-DA7B68DD71DDQ34217461-3190B78E-852B-45AD-B825-D2A3DB239FAAQ35580262-C7F24155-5915-4C77-9B29-03DAF22BBADAQ35594636-C3AE86DF-57D2-4754-98C0-79A3FAC1309FQ35738498-E0416AC2-AA72-477A-BAF6-53AE161AB01BQ35772792-3EDDF075-695C-42CA-8858-9E373C95DB99Q36216416-5BA2D46E-7C5E-4C8E-BBE2-221E3D01A018Q36217085-DA358387-EB07-48E1-9F3E-E0D1744F8C38Q36218668-2FF0C191-CBD2-47C2-A3FA-DB976D60F886Q36353359-ED388808-806C-4136-9097-C4DD6C1925E6Q36529792-A6EFFC83-B6BB-499B-960E-7CF807EACD68Q36920255-62D96097-1D0D-4776-ABA0-8086B7022994Q37219827-4FF1952D-A147-42BE-866B-F2F4D63367C9Q37701841-89BB4ADB-3565-43BD-83B7-277A622288A8Q39508019-3B77111A-1CBF-4222-8B12-7DAC8D7D72D1Q40545045-B95AE448-290D-447A-9078-D22A320B2E17Q41362675-1BF304EE-619A-455B-B6CD-867B85DF6D28Q44897009-29F3D7F4-68A7-447F-8FB0-A65D235E9E62Q50291259-3913A585-D307-47D3-90A3-86133A979CC7
P2860
Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937
description
1986 nî lūn-bûn
@nan
1986 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
name
Purification and characterizat ...... cytic lymphoma cell line U-937
@ast
Purification and characterizat ...... cytic lymphoma cell line U-937
@en
Purification and characterizat ...... cytic lymphoma cell line U-937
@nl
type
label
Purification and characterizat ...... cytic lymphoma cell line U-937
@ast
Purification and characterizat ...... cytic lymphoma cell line U-937
@en
Purification and characterizat ...... cytic lymphoma cell line U-937
@nl
prefLabel
Purification and characterizat ...... cytic lymphoma cell line U-937
@ast
Purification and characterizat ...... cytic lymphoma cell line U-937
@en
Purification and characterizat ...... cytic lymphoma cell line U-937
@nl
P2093
P1476
Purification and characterizat ...... cytic lymphoma cell line U-937
@en
P2093
E. K. Kruithof
F. Bachmann
J. D. Vassalli
R. J. Mattaliano
W. D. Schleuning
P304
11207–11213
P407
P577
1986-08-25T00:00:00Z